You are using an older browser version. Please use a supported version for the best MSN experience.

Orica-GreenEdge admits fault on drug test

Press AssociationPress Association 29/04/2016 By Matt McGeehan

British cyclist Simon Yates has not been suspended and his Orica-GreenEdge team have taken the full blame for a doctor's error which led to a positive drugs test.

Yates tested positive to terbutaline, which is used to relieve asthma symptoms.

The Australian team said an administrative error led to the medicine being administered without the required therapeutic use exemption certificate.

Cycling's governing body the UCI on Friday said Yates has not been provisionally suspended due to the nature of the substance involved.

"The Union Cycliste Internationale (UCI) confirms that British rider Simon Yates has been notified of an adverse analytical finding of terbutaline in a sample collected in the scope of an in-competition control on March 12, 2016," it said.

"As per the UCI's anti-doping rules, such substance does not entail the imposition of a provisional suspension.

"The rider has the right to request and attend the analysis of the B sample.

"At this stage of the procedure, the UCI won't comment any further."

Orica-GreenEdge say they are attempting to clarify the situation with the UCI.

"There has been no wrongdoing on Simon Yates' part," said an Orica GreenEdge statement.

"The team takes full responsibility for this mistake and wishes to underline their support for Simon during this process."

The team were made aware of the positive test on April 22, at stage six of Paris-Nice. He finished sixth on the stage.

The statement added: "The substance was given to Simon Yates in the form an asthma inhaler and accordingly, this was noted by the team doctor on the doping control form, signed at the time of the test.

"The substance was given in an ongoing treatment of Simon Yates' documented asthma problems. However, in this case the team doctor made an administrative error by failing to apply for the TUE required for the use of this treatment.

"The use of terbutaline without a current TUE is the reason it has been flagged as an adverse analytical finding.

"This is solely based on a human error that the doctor in question has taken full responsibility for."

image beaconimage beaconimage beacon